Vertex Pharmaceuticals Statistics
Share Statistics
Vertex Pharmaceuticals has 256.8M
shares outstanding. The number of shares has increased by -0.49%
in one year.
| Shares Outstanding | 256.8M |
| Shares Change (YoY) | -0.49% |
| Shares Change (QoQ) | -0.29% |
| Owned by Institutions (%) | 91.59% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,900 |
| FTD / Avg. Volume | 0.17% |
Short Selling Information
The latest short interest is 3.78M, so 1.47% of the outstanding
shares have been sold short.
| Short Interest | 3.78M |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.66% |
| Short Ratio (days to cover) | 2.87 |
Valuation Ratios
The PE ratio is -193.61 and the forward
PE ratio is 20.87.
Vertex Pharmaceuticals's PEG ratio is
1.69.
| PE Ratio | -193.61 |
| Forward PE | 20.87 |
| PS Ratio | 9.41 |
| Forward PS | 6.4 |
| PB Ratio | 6.32 |
| P/FCF Ratio | -131.21 |
| PEG Ratio | 1.69 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Vertex Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69,
with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.69 |
| Quick Ratio | 2.35 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 3.6 |
| Debt / FCF | -2.21 |
| Interest Coverage | -7.61 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,806,573.77 |
| Profits Per Employee | $-87,803.28 |
| Employee Count | 6,100 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.27 |
Taxes
| Income Tax | 784.1M |
| Effective Tax Rate | 315.53% |
Stock Price Statistics
The stock price has increased by -4.58% in the
last 52 weeks. The beta is 0.51, so Vertex Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.51 |
| 52-Week Price Change | -4.58% |
| 50-Day Moving Average | 477.99 |
| 200-Day Moving Average | 467.6 |
| Relative Strength Index (RSI) | 39.81 |
| Average Volume (20 Days) | 1,742,240 |
Income Statement
In the last 12 months, Vertex Pharmaceuticals had revenue of 11.02B
and earned -535.6M
in profits. Earnings per share was -2.08.
| Revenue | 11.02B |
| Gross Profit | 9.49B |
| Operating Income | -232.9M |
| Net Income | -535.6M |
| EBITDA | 486.3M |
| EBIT | 279.1M |
| Earnings Per Share (EPS) | -2.08 |
Full Income StatementBalance Sheet
The company has 4.57B in cash and 1.75B in
debt, giving a net cash position of 2.82B.
| Cash & Cash Equivalents | 4.57B |
| Total Debt | 1.75B |
| Net Cash | 2.82B |
| Retained Earnings | 9.61B |
| Total Assets | 22.88B |
| Working Capital | 6.23B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -492.6M
and capital expenditures -297.7M, giving a free cash flow of -790.3M.
| Operating Cash Flow | -492.6M |
| Capital Expenditures | -297.7M |
| Free Cash Flow | -790.3M |
| FCF Per Share | -3.07 |
Full Cash Flow StatementMargins
Gross margin is 86.11%, with operating and profit margins of -2.11% and -4.86%.
| Gross Margin | 86.11% |
| Operating Margin | -2.11% |
| Pretax Margin | 2.25% |
| Profit Margin | -4.86% |
| EBITDA Margin | 4.41% |
| EBIT Margin | -2.11% |
| FCF Margin | -7.17% |
